MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck DOI Creative Commons
Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 20, 2025

Rescue therapies of relapsed/refractory (r/r) Hodgkin’s lymphoma (HL) in the third to sixth-line provide major, yet unresolved problems. The MEPED regimen includes nuclear receptor agonists such as pioglitazone and dexamethasone, which counterbalance HL homeostasis, stress response inhibitors, everolimus COX-2 inhibitor, a inducer, low-dose metronomic treosulfan. CR (six seven patients) long-term cCR patients receiving no consolidating allogeneic stem cell transplantation highlight potent salvage therapy advanced refractory HL. edits activities way that mTORC1 becomes non-oncogene addiction bottleneck, hence determining outcome. implications therapeutic paradigm shift toward editing tissue, particularly mTOR addiction, could prove be profound for clinical practice, both terms outcome treatment tolerability. results indicate urgent evaluation schedule multicenter trial r/r

Language: Английский

MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck DOI Creative Commons
Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 20, 2025

Rescue therapies of relapsed/refractory (r/r) Hodgkin’s lymphoma (HL) in the third to sixth-line provide major, yet unresolved problems. The MEPED regimen includes nuclear receptor agonists such as pioglitazone and dexamethasone, which counterbalance HL homeostasis, stress response inhibitors, everolimus COX-2 inhibitor, a inducer, low-dose metronomic treosulfan. CR (six seven patients) long-term cCR patients receiving no consolidating allogeneic stem cell transplantation highlight potent salvage therapy advanced refractory HL. edits activities way that mTORC1 becomes non-oncogene addiction bottleneck, hence determining outcome. implications therapeutic paradigm shift toward editing tissue, particularly mTOR addiction, could prove be profound for clinical practice, both terms outcome treatment tolerability. results indicate urgent evaluation schedule multicenter trial r/r

Language: Английский

Citations

0